Challenges in The Diagnosis and Management of Idiopathic Inflammatory Myopathy: A Case Report
Alexander Tonny Limono1*, Pande Ketut Kurniari1, Gede Kambayana2
Abstract
Background: Idiopathic inflammatory myopathy (IIM) is a group of heterogeneous disorders characterized by muscle weakness and muscle inflammation, elevated muscle enzyme, a sign of muscular inflammation, and other extra muscular manifestations. Due to how rare IIM is, as well as its lack of targeted treatments and the heterogeneity of the clinical presentation, significant challenges are posed to treatment deliveries. Case Illustration: A 30-year-old woman came with complaints of weakness in all four extremities 8 months ago accompanied by difficulty swallowing. The weakness worsened to the point where the patient had shortness of breath and a fever. Upon arrival at the hospital, the patient was in respiratory failure and intubated. Laboratory examination results showed an increase in serum creatine kinase (14.977 U/L), increased liver enzymes, and inflammatory biomarkers such as CRP and procalcitonin. Muscle biopsy results showed muscular dystrophy. Chest X-ray showed cardiomegaly with signs of pulmonary inflammation and pleural effusion. The patient received steroid therapy, cyclophosphamide, and antibiotic management for pneumonia. During treatment, the patient’s condition worsened and she was declared dead due to sepsis. Conclusion: IIM is a rare disease and has various clinical variations. Extra muscular manifestations such as pulmonary disease complicate the management of IIM.
Keywords
idiopathic inflammatory myopathy; autoimmune disease; muscle inflammation.
Cite This Article
Limono, A. T., Kurniari, P. K., Kambayana, G. (2024). Challenges in The Diagnosis and Management of Idiopathic Inflammatory Myopathy: A Case Report. International Journal of Scientific Advances (IJSCIA), Volume 5| Issue 5: Sep-Oct 2024, Pages 928-931, URL: https://www.ijscia.com/wp-content/uploads/2024/09/Volume5-Issue5-Sep-Oct-No.667-928-931.pdf
Volume 5 | Issue 5: Sep-Oct 2024
